非酒精性脂肪性肝病与肠道菌群失调新观点

doi:10.3969/j.issn.1672-5069.2014.03.035

摘要/Abstract

摘要： 非酒精性脂肪性肝病（NAFLD）在世界范围内患病率逐渐升高,“二次打击学说”发病机制已经被认可,但是具体的病理生理学发病机制还不完全清楚。近期,已有大量研究的新观点来解释肠道菌群在NAFLD发病机制中的作用,包括调节肠粘膜通透性、低水平炎症反应和免疫平衡,调节饮食胆碱代谢,调节胆汁酸代谢和增加细菌产生的内源性乙醇等。这些因素在分子水平上解释了肠道菌群如何促发NAFLD的发生,并进一步诱导其向非酒精性脂肪性肝炎（NASH）进展。

关键词: 非酒精性脂肪性肝病, 肠道菌群, 脂多糖

Abstract: Non-alcoholic fatty liver diseases （NAFLD） has an increasing worldwide prevalence. A ‘two-hit’ mechanism has been accepted,however,its pathogenesis remains to be clarified. Recently,some new findings about gut microbiota in NAFLD have emerged. It might be involved in gut permeability,low-grade inflammation and immune inbalance,and it is believed that it modulates dietary choline metabolism,regulates bile acid metabolism and produces endogenous ethanol. All of these factors are molecular mechanisms by which the microbiota can induce NAFLD or has some roles in the process from NAFLD to overt non-alcoholic steatohepatitis. This review summarizes the main literature findings about the relationships between gut microbiota and NAFLD.

Key words: Non-alcoholic fatty liver diseases, Gut microbiota, Lipopolysaccharide

孙露综述, 鲁晓岚审校. 非酒精性脂肪性肝病与肠道菌群失调新观点[J]. 实用肝脏病杂志, 2014, 17(3): 333-335.

Sun Lu, Lu Xiaolan. Perspectives in gut microbiota in non-alcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(3): 333-335.

参考文献

[1] Ley RE,Turnbaugh PJ,Klein S. Gordon microbial ecology: human gut microbes associated with obesity. Nature,2006,444 （7122）:1022-1023.
[2] Tilg H,Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease:the multiple parallel hits hypothesis. Hepatology,2010,52（5）:1836-1846.
[3] Bhatia LS,Curzen NP,Calder PC et al. Non-alcoholic fatty liver disease:a new and important cardiovascular risk factor Eur Heart J,2012,33:1190-1200.
[4] Soderberg C,Stal P,Askling J et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology,2010,51:595-602.
[5] Backhed F,Ding H,Wang T et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA,2004,101:15718-15723.
[6] Drenick EJ,Fisler J,Johnson D. Hepatic steatosis after intestinal bypass-prevention and reversal by metronidazole,irrespective of protein-calorie malnutrition. Gastroenterology,1982,82:535-548.
[7] Cani PD,Amar J,Iglesias MA et al. Metabolic endotoxemia initiatesobesity and insulin resistance. Diabetes,2007,56:1761-1772.
[8] Saberi M,Woods NB,de Luca Cet al. Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab,2009,10:419-429.
[9] Backhed F,Ding H,Wang T et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA,2004,101:15718-15723
[10] Alisi A,Ceccarelli S,Panera N et al. Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Front Cell Infect Microbiol,2012,2:132.
[11] Machado MV,Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol,2012,11:440-449.
[12] Harte AL,da Silva NF,Creely SJ et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm （Lond）,2010,7: 15.
[13] Fujimoto Y,Fukase K. Structures,synthesis,and human Nod1 stimulation of immunostimulatory bacterial peptidoglycan fragments in the environment. J Nat Prod,2011,74:518-525.
[14] Verdam FJ,Rensen SS,Driessen A et al. Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis. J Clin Gastroenterol,2011,45:149-152.
[15] Miele L,Valenza V,La Torre G et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology,2009,49:1877-1887.
[16] Wigg AJ,Roberts-Thomson IC,Dymock RB et al. The role of small intestinal bacterial overgrowth,intestinal permeability,endotoxaemia,and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. Gut,2001,48:206-211.
[17] Gabele E,Dostert K,Hofmann C et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol,2011,55:1391-1399.
[18] De Gottardi A,McCoy KD. Evaluation of the gut barrier to intestinal bacteria in non-alcoholic fatty liver disease. J Hepatol,2011,55:1181-1183.
[19] Wang Z,Klipfell E,Bennett BJ et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature,2011,472:57-63.
[20] Spencer MD,Hamp TJ,Reid RW,et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology,2011,140:976-986.
[21] Corbin KD,Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol,2012,28:159-165.
[22] Yokota A,Fukiya S,Islam KB et al. Is bile acid a determinant of the gut microbiota on a high-fat diet Gut Microbes,2012,3: 455-459.
[23] Turnbaugh PJ. Microbiology:fat,bile and gut microbes. Nature, 2012,487:47-48.
[24] Dekaney CM,von Allmen DC,Garrison AP,et al. Bacterial-dependent up-regulation of intestinal bile acid binding protein and transport is FXR mediated following ileo-cecal resection. Surgery,2008,144:174-181.
[25] Trauner M,Claudel T,Fickert P et al. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis,2010,28:220-224.
[26] Thomas C,Gioiello A,Noriega L,et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab,2009,10: 167-177.
[27] Keitel V,Haussinger D. Perspective:TGR5 （Gpbar-1） in liver physiology and disease. Clin Res Hepatol Gastroenterol,2012,36:412-419.
[28] Tremaroli V,Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature,2012,489:242-249.
[29] Zhu L,Baker SS,Gill C,et al. Characterization of the gut microbiome in non-alcoholic steatohepatitis（NASH） patients:a connection between endogenous alcohol and NASH. Hepatology,2012,doi:10.1002/hep.26093 [Epub ahead of print].
[30] Volynets V,Kuper MA,Strahl S et al. Nutrition, intestinal permeability,and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease（NAFLD）. Dig Dis Sci,2012,57:1932-1941.
[31] Li Z,Yang S,Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology,2003,37:343-350.
[32] Ma X,Hua J,Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol,2008,49:821-830.
[33] Loguercio C,Federico A,Tuccillo C et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol,2005,39:540-543.
[34] Million M,Angelakis E,Paul M et al. Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. Microb Pathog,2012,53:100-108.
[35] Aller R, De Luis DA,Izaola O,et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver diseasepatients:a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci,2011,15:1090-1095.
[36] Delzenne NM,Cani PD,Neyrinck AM. Modulation of glucagon-like peptide 1 and energy metabolism by inulin and oligofructose:experimental data. J Nutr,2007,137（Suppl 11）:2547S-2551S.
[37] Compare D,Coccoli P,Rocco A,et al. Gut-liver axis: the impact of gut microbiota on non- alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis,2012,22:471-476.
[38] Daubioul CA,Horsmans Y,Lambert P,et al. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr, 2005,59:723-726.